Drug lookup | Fillwise

Accel-Ondansetron ODT (Tablet) · DIN 02535319 · 4mg ·

Limited Use — Reason for Use code 215, 216, 217, 218, 454, 696 requiredMarketed · checked 2026-09-02

Write on scriptLU code 215, 216, 217, 218, 454, 696 (patient must meet the criteria below)

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ontario Limited Use criteria — code 215, 216, 217, 218, 454, 696

Reason for Use code 215 For the treatment of emesis in cancer patients receiving highly emetogenic chemotherapy. Coverage limit: LU Authorization Period: 1 year Reason for Use code 216 For patients receiving intravenous chemotherapy or radiation therapy who have not experienced adequate control with other available anti-emetics. Coverage limit: LU Authorization Period: 1 year Reason for Use code 217 For patients receiving intravenous chemotherapy or radiation therapy who experience intolerable side effects with other anti-emetics. Coverage limit: LU Authorization Period: 1 year Reason for Use code 218 For the treatment of emesis in patients receiving radiation therapy which consists of single fraction treatment to the abdominal cavity, hemi-body irradiation and total body irradiation. Coverage limit: The therapeutic value of Ondansetron Hydrochloride more than 24 hours after the last dose of chemotherapy is unproven. Coverage limit: LU Authorization Period: 1 year Reason for Use code 454 For the treatment of emesis in cancer patients receiving moderately emetogenic chemotherapy (MEC) regimens. Coverage limit: LU Authorization Period: 1 year Reason for Use code 696 For the treatment of emesis in patients receiving palliative care who are refractory to, intolerant to, or have a contraindication to at least two other anti-emetics. Note: Pharmacists and prescribers should be informed of and stay current with a drug product's official indications in accordance with Health Canada's approved product monograph. Some aspects of the above criteria may differ from the official indications as described in the product monograph for the ondansetron product. The Executive Officer's funding of drug products is informed by advice from experts that consider evidence regarding the safety, clinical efficacy, and cost-effectiveness of drug products. Coverage limit: LU Authorization Period: 1 year

1 brand, same coverage

Accel-Ondansetron ODT (Tablet) · DIN 02535319 Manufacturer: Accel Pharma Inc.; listing date 2024-02-29 Health Canada: Marketed since 2023-12-19 · brand ACCEL-ONDANSETRON ODT · ATC A04AA01 ONDANSETRON · form Tablet (orally-disintegrating) · route Oral · ingredients ONDANSETRON 4 MG · company Accel pharma inc · schedule Prescription

Check this DIN again · Health Canada product record

Accel-Ondansetron ODT (Tablet): Formulary list price $2.5450/unit (unit not stated in source; not the patient's cost)

Ministry pays: $2.5450 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102417 · Verify on the e-Formulary ↗ (DIN 02535319)

Source record

DIN 02535319: Accel-Ondansetron ODT (Tablet) Raw flags: sec12=Y, sec3=Y Item: 562200029; group id 671; item number 1662; lccId 00102; manufacturer id ACC Source form: None; strength: 4mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $2.5450; ministry $2.5450 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02535319 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102417

Interchangeable products

Auro-Ondansetron ODT (Tablet) · DIN 02511282 · $2.5450 Jamp Ondansetron ODF (Film) · DIN 02541351 · $2.5450 Mar-Ondansetron ODT Tablet · DIN 02514966 · $2.5450 Mint-Ondansetron ODT (Tablet) · DIN 02487330 · $2.5450 Ondansetron ODT (Tablet) · DIN 02481723 · $2.5450 Ondansetron ODT (Tablet) · DIN 02519232 · $2.5450 Ondansetron ODT (Tablet) · DIN 02524279 · $2.5450 Ondissolve ODF (Film) · DIN 02389983 · $2.5450 PMS-Ondansetron ODT Tablet · DIN 02519445 · $2.5450 Zofran ODT (Tablet) · DIN 02239372 · not recorded

Shortage status: resolved shortage (ended 2025-06-04); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02535319

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Auro-Ondansetron ODT (Tablet) · DIN 02511282 · 4mg ·

Limited Use — Reason for Use code 215, 216, 217, 218, 454, 696 requiredMarketed · checked 2026-09-02

Write on scriptLU code 215, 216, 217, 218, 454, 696 (patient must meet the criteria below)

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ontario Limited Use criteria — code 215, 216, 217, 218, 454, 696

Reason for Use code 215 For the treatment of emesis in cancer patients receiving highly emetogenic chemotherapy. Coverage limit: LU Authorization Period: 1 year Reason for Use code 216 For patients receiving intravenous chemotherapy or radiation therapy who have not experienced adequate control with other available anti-emetics. Coverage limit: LU Authorization Period: 1 year Reason for Use code 217 For patients receiving intravenous chemotherapy or radiation therapy who experience intolerable side effects with other anti-emetics. Coverage limit: LU Authorization Period: 1 year Reason for Use code 218 For the treatment of emesis in patients receiving radiation therapy which consists of single fraction treatment to the abdominal cavity, hemi-body irradiation and total body irradiation. Coverage limit: The therapeutic value of Ondansetron Hydrochloride more than 24 hours after the last dose of chemotherapy is unproven. Coverage limit: LU Authorization Period: 1 year Reason for Use code 454 For the treatment of emesis in cancer patients receiving moderately emetogenic chemotherapy (MEC) regimens. Coverage limit: LU Authorization Period: 1 year Reason for Use code 696 For the treatment of emesis in patients receiving palliative care who are refractory to, intolerant to, or have a contraindication to at least two other anti-emetics. Note: Pharmacists and prescribers should be informed of and stay current with a drug product's official indications in accordance with Health Canada's approved product monograph. Some aspects of the above criteria may differ from the official indications as described in the product monograph for the ondansetron product. The Executive Officer's funding of drug products is informed by advice from experts that consider evidence regarding the safety, clinical efficacy, and cost-effectiveness of drug products. Coverage limit: LU Authorization Period: 1 year

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Auro-Ondansetron ODT (Tablet) · DIN 02511282 Manufacturer: Auro Pharma Inc.; listing date 2022-03-31 Health Canada: Marketed since 2021-12-23 · brand AURO-ONDANSETRON ODT · ATC A04AA01 ONDANSETRON · form Tablet (orally-disintegrating) · route Oral · ingredients ONDANSETRON 4 MG · company Auro pharma inc · schedule Prescription

Check this DIN again · Health Canada product record

Ministry pays: $2.5450 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100050 · Verify on the e-Formulary ↗ (DIN 02511282)

Source record

DIN 02511282: Auro-Ondansetron ODT (Tablet) Raw flags: sec12=Y, sec3=Y Item: 562200029; group id 671; item number 1662; lccId 00102; manufacturer id AUR Source form: None; strength: 4mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $3.2720; ministry $2.5450 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02511282 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100050

Interchangeable products

Accel-Ondansetron ODT (Tablet) · DIN 02535319 · $2.5450 Jamp Ondansetron ODF (Film) · DIN 02541351 · $2.5450 Mar-Ondansetron ODT Tablet · DIN 02514966 · $2.5450 Mint-Ondansetron ODT (Tablet) · DIN 02487330 · $2.5450 Ondansetron ODT (Tablet) · DIN 02481723 · $2.5450 Ondansetron ODT (Tablet) · DIN 02519232 · $2.5450 Ondansetron ODT (Tablet) · DIN 02524279 · $2.5450 Ondissolve ODF (Film) · DIN 02389983 · $2.5450 PMS-Ondansetron ODT Tablet · DIN 02519445 · $2.5450 Zofran ODT (Tablet) · DIN 02239372 · not recorded

Shortage status: resolved shortage (ended 2025-01-03); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02511282

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp Ondansetron ODF (Film) · DIN 02541351 · 4mg ·

Limited Use — Reason for Use code 215, 216, 217, 218, 454, 696 requiredMarketed · checked 2026-09-02

Write on scriptLU code 215, 216, 217, 218, 454, 696 (patient must meet the criteria below)

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ontario Limited Use criteria — code 215, 216, 217, 218, 454, 696

Reason for Use code 215 For the treatment of emesis in cancer patients receiving highly emetogenic chemotherapy. Coverage limit: LU Authorization Period: 1 year Reason for Use code 216 For patients receiving intravenous chemotherapy or radiation therapy who have not experienced adequate control with other available anti-emetics. Coverage limit: LU Authorization Period: 1 year Reason for Use code 217 For patients receiving intravenous chemotherapy or radiation therapy who experience intolerable side effects with other anti-emetics. Coverage limit: LU Authorization Period: 1 year Reason for Use code 218 For the treatment of emesis in patients receiving radiation therapy which consists of single fraction treatment to the abdominal cavity, hemi-body irradiation and total body irradiation. Coverage limit: The therapeutic value of Ondansetron Hydrochloride more than 24 hours after the last dose of chemotherapy is unproven. Coverage limit: LU Authorization Period: 1 year Reason for Use code 454 For the treatment of emesis in cancer patients receiving moderately emetogenic chemotherapy (MEC) regimens. Coverage limit: LU Authorization Period: 1 year Reason for Use code 696 For the treatment of emesis in patients receiving palliative care who are refractory to, intolerant to, or have a contraindication to at least two other anti-emetics. Note: Pharmacists and prescribers should be informed of and stay current with a drug product's official indications in accordance with Health Canada's approved product monograph. Some aspects of the above criteria may differ from the official indications as described in the product monograph for the ondansetron product. The Executive Officer's funding of drug products is informed by advice from experts that consider evidence regarding the safety, clinical efficacy, and cost-effectiveness of drug products. Coverage limit: LU Authorization Period: 1 year

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Jamp Ondansetron ODF (Film) · DIN 02541351 Manufacturer: Jamp Pharma Corporation; listing date 2024-06-28 Health Canada: Marketed since 2024-05-10 · brand JAMP ONDANSETRON ODF · ATC A04AA01 ONDANSETRON · form Film (soluble) · route Oral · ingredients ONDANSETRON 4 MG · company Jamp pharma corporation · schedule Prescription

Check this DIN again · Health Canada product record

Ministry pays: $2.5450 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103000 · Verify on the e-Formulary ↗ (DIN 02541351)

Source record

DIN 02541351: Jamp Ondansetron ODF (Film) Raw flags: sec12=Y, sec3=Y Item: 562200029; group id 671; item number 1662; lccId 00102; manufacturer id JPC Source form: None; strength: 4mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $3.2720; ministry $2.5450 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02541351 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103000

Interchangeable products

Accel-Ondansetron ODT (Tablet) · DIN 02535319 · $2.5450 Auro-Ondansetron ODT (Tablet) · DIN 02511282 · $2.5450 Mar-Ondansetron ODT Tablet · DIN 02514966 · $2.5450 Mint-Ondansetron ODT (Tablet) · DIN 02487330 · $2.5450 Ondansetron ODT (Tablet) · DIN 02481723 · $2.5450 Ondansetron ODT (Tablet) · DIN 02519232 · $2.5450 Ondansetron ODT (Tablet) · DIN 02524279 · $2.5450 Ondissolve ODF (Film) · DIN 02389983 · $2.5450 PMS-Ondansetron ODT Tablet · DIN 02519445 · $2.5450 Zofran ODT (Tablet) · DIN 02239372 · not recorded

Shortage status: active shortage (reported 2026-06-30, estimated to end 2026-09-25, last updated 2026-07-03); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02541351

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mar-Ondansetron ODT Tablet · DIN 02514966 · 4mg ·

Limited Use — Reason for Use code 215, 216, 217, 218, 454, 696 requiredMarketed · checked 2026-09-02

Write on scriptLU code 215, 216, 217, 218, 454, 696 (patient must meet the criteria below)

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ontario Limited Use criteria — code 215, 216, 217, 218, 454, 696

Reason for Use code 215 For the treatment of emesis in cancer patients receiving highly emetogenic chemotherapy. Coverage limit: LU Authorization Period: 1 year Reason for Use code 216 For patients receiving intravenous chemotherapy or radiation therapy who have not experienced adequate control with other available anti-emetics. Coverage limit: LU Authorization Period: 1 year Reason for Use code 217 For patients receiving intravenous chemotherapy or radiation therapy who experience intolerable side effects with other anti-emetics. Coverage limit: LU Authorization Period: 1 year Reason for Use code 218 For the treatment of emesis in patients receiving radiation therapy which consists of single fraction treatment to the abdominal cavity, hemi-body irradiation and total body irradiation. Coverage limit: The therapeutic value of Ondansetron Hydrochloride more than 24 hours after the last dose of chemotherapy is unproven. Coverage limit: LU Authorization Period: 1 year Reason for Use code 454 For the treatment of emesis in cancer patients receiving moderately emetogenic chemotherapy (MEC) regimens. Coverage limit: LU Authorization Period: 1 year Reason for Use code 696 For the treatment of emesis in patients receiving palliative care who are refractory to, intolerant to, or have a contraindication to at least two other anti-emetics. Note: Pharmacists and prescribers should be informed of and stay current with a drug product's official indications in accordance with Health Canada's approved product monograph. Some aspects of the above criteria may differ from the official indications as described in the product monograph for the ondansetron product. The Executive Officer's funding of drug products is informed by advice from experts that consider evidence regarding the safety, clinical efficacy, and cost-effectiveness of drug products. Coverage limit: LU Authorization Period: 1 year

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Mar-Ondansetron ODT Tablet · DIN 02514966 Manufacturer: Marcan Pharmaceuticals Inc.; listing date 2022-05-31 Health Canada: Marketed since 2022-04-05 · brand MAR-ONDANSETRON ODT · ATC A04AA01 ONDANSETRON · form Tablet (orally-disintegrating) · route Oral · ingredients ONDANSETRON 4 MG · company Marcan pharmaceuticals inc · schedule Prescription

Check this DIN again · Health Canada product record

Ministry pays: $2.5450 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100436 · Verify on the e-Formulary ↗ (DIN 02514966)

Source record

DIN 02514966: Mar-Ondansetron ODT Tablet Raw flags: sec12=Y, sec3=Y Item: 562200029; group id 671; item number 1662; lccId 00102; manufacturer id MAR Source form: None; strength: 4mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $3.2720; ministry $2.5450 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02514966 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100436

Interchangeable products

Accel-Ondansetron ODT (Tablet) · DIN 02535319 · $2.5450 Auro-Ondansetron ODT (Tablet) · DIN 02511282 · $2.5450 Jamp Ondansetron ODF (Film) · DIN 02541351 · $2.5450 Mint-Ondansetron ODT (Tablet) · DIN 02487330 · $2.5450 Ondansetron ODT (Tablet) · DIN 02481723 · $2.5450 Ondansetron ODT (Tablet) · DIN 02519232 · $2.5450 Ondansetron ODT (Tablet) · DIN 02524279 · $2.5450 Ondissolve ODF (Film) · DIN 02389983 · $2.5450 PMS-Ondansetron ODT Tablet · DIN 02519445 · $2.5450 Zofran ODT (Tablet) · DIN 02239372 · not recorded

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02514966

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mint-Ondansetron ODT (Tablet) · DIN 02487330 · 4mg ·

Limited Use — Reason for Use code 215, 216, 217, 218, 454, 696 requiredMarketed · checked 2026-09-02

Write on scriptLU code 215, 216, 217, 218, 454, 696 (patient must meet the criteria below)

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ontario Limited Use criteria — code 215, 216, 217, 218, 454, 696

Reason for Use code 215 For the treatment of emesis in cancer patients receiving highly emetogenic chemotherapy. Coverage limit: LU Authorization Period: 1 year Reason for Use code 216 For patients receiving intravenous chemotherapy or radiation therapy who have not experienced adequate control with other available anti-emetics. Coverage limit: LU Authorization Period: 1 year Reason for Use code 217 For patients receiving intravenous chemotherapy or radiation therapy who experience intolerable side effects with other anti-emetics. Coverage limit: LU Authorization Period: 1 year Reason for Use code 218 For the treatment of emesis in patients receiving radiation therapy which consists of single fraction treatment to the abdominal cavity, hemi-body irradiation and total body irradiation. Coverage limit: The therapeutic value of Ondansetron Hydrochloride more than 24 hours after the last dose of chemotherapy is unproven. Coverage limit: LU Authorization Period: 1 year Reason for Use code 454 For the treatment of emesis in cancer patients receiving moderately emetogenic chemotherapy (MEC) regimens. Coverage limit: LU Authorization Period: 1 year Reason for Use code 696 For the treatment of emesis in patients receiving palliative care who are refractory to, intolerant to, or have a contraindication to at least two other anti-emetics. Note: Pharmacists and prescribers should be informed of and stay current with a drug product's official indications in accordance with Health Canada's approved product monograph. Some aspects of the above criteria may differ from the official indications as described in the product monograph for the ondansetron product. The Executive Officer's funding of drug products is informed by advice from experts that consider evidence regarding the safety, clinical efficacy, and cost-effectiveness of drug products. Coverage limit: LU Authorization Period: 1 year

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Mint-Ondansetron ODT (Tablet) · DIN 02487330 Manufacturer: Mint Pharmaceuticals Inc.; listing date 2020-04-30 Health Canada: Marketed since 2019-10-16 · brand MINT-ONDANSETRON ODT · ATC A04AA01 ONDANSETRON · form Tablet (orally-disintegrating) · route Oral · ingredients ONDANSETRON 4 MG · company Mint pharmaceuticals inc · schedule Prescription

Check this DIN again · Health Canada product record

Ministry pays: $2.5450 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97750 · Verify on the e-Formulary ↗ (DIN 02487330)

Source record

DIN 02487330: Mint-Ondansetron ODT (Tablet) Raw flags: sec12=Y, sec3=Y Item: 562200029; group id 671; item number 1662; lccId 00102; manufacturer id MIN Source form: None; strength: 4mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $3.2720; ministry $2.5450 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02487330 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97750

Interchangeable products

Accel-Ondansetron ODT (Tablet) · DIN 02535319 · $2.5450 Auro-Ondansetron ODT (Tablet) · DIN 02511282 · $2.5450 Jamp Ondansetron ODF (Film) · DIN 02541351 · $2.5450 Mar-Ondansetron ODT Tablet · DIN 02514966 · $2.5450 Ondansetron ODT (Tablet) · DIN 02481723 · $2.5450 Ondansetron ODT (Tablet) · DIN 02519232 · $2.5450 Ondansetron ODT (Tablet) · DIN 02524279 · $2.5450 Ondissolve ODF (Film) · DIN 02389983 · $2.5450 PMS-Ondansetron ODT Tablet · DIN 02519445 · $2.5450 Zofran ODT (Tablet) · DIN 02239372 · not recorded

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02487330

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Ondansetron ODT (Tablet) · DIN 02481723 · 4mg ·

Limited Use — Reason for Use code 215, 216, 217, 218, 454, 696 requiredMarketed · checked 2026-09-02

Write on scriptLU code 215, 216, 217, 218, 454, 696 (patient must meet the criteria below)

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ontario Limited Use criteria — code 215, 216, 217, 218, 454, 696

Reason for Use code 215 For the treatment of emesis in cancer patients receiving highly emetogenic chemotherapy. Coverage limit: LU Authorization Period: 1 year Reason for Use code 216 For patients receiving intravenous chemotherapy or radiation therapy who have not experienced adequate control with other available anti-emetics. Coverage limit: LU Authorization Period: 1 year Reason for Use code 217 For patients receiving intravenous chemotherapy or radiation therapy who experience intolerable side effects with other anti-emetics. Coverage limit: LU Authorization Period: 1 year Reason for Use code 218 For the treatment of emesis in patients receiving radiation therapy which consists of single fraction treatment to the abdominal cavity, hemi-body irradiation and total body irradiation. Coverage limit: The therapeutic value of Ondansetron Hydrochloride more than 24 hours after the last dose of chemotherapy is unproven. Coverage limit: LU Authorization Period: 1 year Reason for Use code 454 For the treatment of emesis in cancer patients receiving moderately emetogenic chemotherapy (MEC) regimens. Coverage limit: LU Authorization Period: 1 year Reason for Use code 696 For the treatment of emesis in patients receiving palliative care who are refractory to, intolerant to, or have a contraindication to at least two other anti-emetics. Note: Pharmacists and prescribers should be informed of and stay current with a drug product's official indications in accordance with Health Canada's approved product monograph. Some aspects of the above criteria may differ from the official indications as described in the product monograph for the ondansetron product. The Executive Officer's funding of drug products is informed by advice from experts that consider evidence regarding the safety, clinical efficacy, and cost-effectiveness of drug products. Coverage limit: LU Authorization Period: 1 year

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Ondansetron ODT (Tablet) · DIN 02481723 Manufacturer: Sandoz Canada Inc.; listing date 2019-07-31 Health Canada: Marketed since 2019-05-15 · brand ONDANSETRON ODT · ATC A04AA01 ONDANSETRON · form Tablet (orally-disintegrating) · route Oral · ingredients ONDANSETRON 4 MG · company Sandoz canada incorporated · schedule Prescription

Check this DIN again · Health Canada product record

Ministry pays: $2.5450 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97221 · Verify on the e-Formulary ↗ (DIN 02481723)

Source record

DIN 02481723: Ondansetron ODT (Tablet) Raw flags: sec12=Y, sec3=Y Item: 562200029; group id 671; item number 1662; lccId 00102; manufacturer id SDZ Source form: None; strength: 4mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $3.2720; ministry $2.5450 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02481723 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97221

Interchangeable products

Accel-Ondansetron ODT (Tablet) · DIN 02535319 · $2.5450 Auro-Ondansetron ODT (Tablet) · DIN 02511282 · $2.5450 Jamp Ondansetron ODF (Film) · DIN 02541351 · $2.5450 Mar-Ondansetron ODT Tablet · DIN 02514966 · $2.5450 Mint-Ondansetron ODT (Tablet) · DIN 02487330 · $2.5450 Ondansetron ODT (Tablet) · DIN 02519232 · $2.5450 Ondansetron ODT (Tablet) · DIN 02524279 · $2.5450 Ondissolve ODF (Film) · DIN 02389983 · $2.5450 PMS-Ondansetron ODT Tablet · DIN 02519445 · $2.5450 Zofran ODT (Tablet) · DIN 02239372 · not recorded

Shortage status: resolved shortage (ended 2026-03-02); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02481723

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Ondansetron ODT (Tablet) · DIN 02519232 · 4mg ·

Limited Use — Reason for Use code 215, 216, 217, 218, 454, 696 requiredMarketed · checked 2026-09-02

Write on scriptLU code 215, 216, 217, 218, 454, 696 (patient must meet the criteria below)

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ontario Limited Use criteria — code 215, 216, 217, 218, 454, 696

Reason for Use code 215 For the treatment of emesis in cancer patients receiving highly emetogenic chemotherapy. Coverage limit: LU Authorization Period: 1 year Reason for Use code 216 For patients receiving intravenous chemotherapy or radiation therapy who have not experienced adequate control with other available anti-emetics. Coverage limit: LU Authorization Period: 1 year Reason for Use code 217 For patients receiving intravenous chemotherapy or radiation therapy who experience intolerable side effects with other anti-emetics. Coverage limit: LU Authorization Period: 1 year Reason for Use code 218 For the treatment of emesis in patients receiving radiation therapy which consists of single fraction treatment to the abdominal cavity, hemi-body irradiation and total body irradiation. Coverage limit: The therapeutic value of Ondansetron Hydrochloride more than 24 hours after the last dose of chemotherapy is unproven. Coverage limit: LU Authorization Period: 1 year Reason for Use code 454 For the treatment of emesis in cancer patients receiving moderately emetogenic chemotherapy (MEC) regimens. Coverage limit: LU Authorization Period: 1 year Reason for Use code 696 For the treatment of emesis in patients receiving palliative care who are refractory to, intolerant to, or have a contraindication to at least two other anti-emetics. Note: Pharmacists and prescribers should be informed of and stay current with a drug product's official indications in accordance with Health Canada's approved product monograph. Some aspects of the above criteria may differ from the official indications as described in the product monograph for the ondansetron product. The Executive Officer's funding of drug products is informed by advice from experts that consider evidence regarding the safety, clinical efficacy, and cost-effectiveness of drug products. Coverage limit: LU Authorization Period: 1 year

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Ondansetron ODT (Tablet) · DIN 02519232 Manufacturer: Jamp Pharma Corporation; listing date 2022-06-30 Health Canada: Marketed since 2022-04-25 · brand ONDANSETRON ODT · ATC A04AA01 ONDANSETRON · form Tablet (orally-disintegrating) · route Oral · ingredients ONDANSETRON 4 MG · company Jamp pharma corporation · schedule Prescription

Check this DIN again · Health Canada product record

Ministry pays: $2.5450 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100851 · Verify on the e-Formulary ↗ (DIN 02519232)

Source record

DIN 02519232: Ondansetron ODT (Tablet) Raw flags: sec12=Y, sec3=Y Item: 562200029; group id 671; item number 1662; lccId 00102; manufacturer id JPC Source form: None; strength: 4mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $3.2720; ministry $2.5450 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02519232 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100851

Interchangeable products

Accel-Ondansetron ODT (Tablet) · DIN 02535319 · $2.5450 Auro-Ondansetron ODT (Tablet) · DIN 02511282 · $2.5450 Jamp Ondansetron ODF (Film) · DIN 02541351 · $2.5450 Mar-Ondansetron ODT Tablet · DIN 02514966 · $2.5450 Mint-Ondansetron ODT (Tablet) · DIN 02487330 · $2.5450 Ondansetron ODT (Tablet) · DIN 02481723 · $2.5450 Ondansetron ODT (Tablet) · DIN 02524279 · $2.5450 Ondissolve ODF (Film) · DIN 02389983 · $2.5450 PMS-Ondansetron ODT Tablet · DIN 02519445 · $2.5450 Zofran ODT (Tablet) · DIN 02239372 · not recorded

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02519232

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Ondansetron ODT (Tablet) · DIN 02524279 · 4mg ·

Limited Use — Reason for Use code 215, 216, 217, 218, 454, 696 requiredMarketed · checked 2026-09-02

Write on scriptLU code 215, 216, 217, 218, 454, 696 (patient must meet the criteria below)

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ontario Limited Use criteria — code 215, 216, 217, 218, 454, 696

Reason for Use code 215 For the treatment of emesis in cancer patients receiving highly emetogenic chemotherapy. Coverage limit: LU Authorization Period: 1 year Reason for Use code 216 For patients receiving intravenous chemotherapy or radiation therapy who have not experienced adequate control with other available anti-emetics. Coverage limit: LU Authorization Period: 1 year Reason for Use code 217 For patients receiving intravenous chemotherapy or radiation therapy who experience intolerable side effects with other anti-emetics. Coverage limit: LU Authorization Period: 1 year Reason for Use code 218 For the treatment of emesis in patients receiving radiation therapy which consists of single fraction treatment to the abdominal cavity, hemi-body irradiation and total body irradiation. Coverage limit: The therapeutic value of Ondansetron Hydrochloride more than 24 hours after the last dose of chemotherapy is unproven. Coverage limit: LU Authorization Period: 1 year Reason for Use code 454 For the treatment of emesis in cancer patients receiving moderately emetogenic chemotherapy (MEC) regimens. Coverage limit: LU Authorization Period: 1 year Reason for Use code 696 For the treatment of emesis in patients receiving palliative care who are refractory to, intolerant to, or have a contraindication to at least two other anti-emetics. Note: Pharmacists and prescribers should be informed of and stay current with a drug product's official indications in accordance with Health Canada's approved product monograph. Some aspects of the above criteria may differ from the official indications as described in the product monograph for the ondansetron product. The Executive Officer's funding of drug products is informed by advice from experts that consider evidence regarding the safety, clinical efficacy, and cost-effectiveness of drug products. Coverage limit: LU Authorization Period: 1 year

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Ondansetron ODT (Tablet) · DIN 02524279 Manufacturer: Sanis Health Inc.; listing date 2023-11-30 Health Canada: Marketed since 2025-07-08 · brand ONDANSETRON ODT · ATC A04AA01 ONDANSETRON · form Tablet (orally-disintegrating) · route Oral · ingredients ONDANSETRON 4 MG · company Sanis health inc · schedule Prescription

Check this DIN again · Health Canada product record

Ministry pays: $2.5450 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101331 · Verify on the e-Formulary ↗ (DIN 02524279)

Source record

DIN 02524279: Ondansetron ODT (Tablet) Raw flags: sec12=Y, sec3=Y Item: 562200029; group id 671; item number 1662; lccId 00102; manufacturer id SAI Source form: None; strength: 4mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $3.2720; ministry $2.5450 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02524279 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101331

Interchangeable products

Accel-Ondansetron ODT (Tablet) · DIN 02535319 · $2.5450 Auro-Ondansetron ODT (Tablet) · DIN 02511282 · $2.5450 Jamp Ondansetron ODF (Film) · DIN 02541351 · $2.5450 Mar-Ondansetron ODT Tablet · DIN 02514966 · $2.5450 Mint-Ondansetron ODT (Tablet) · DIN 02487330 · $2.5450 Ondansetron ODT (Tablet) · DIN 02481723 · $2.5450 Ondansetron ODT (Tablet) · DIN 02519232 · $2.5450 Ondissolve ODF (Film) · DIN 02389983 · $2.5450 PMS-Ondansetron ODT Tablet · DIN 02519445 · $2.5450 Zofran ODT (Tablet) · DIN 02239372 · not recorded

Shortage status: resolved shortage (ended 2025-12-03); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02524279

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Ondissolve ODF (Film) · DIN 02389983 · 4mg ·

Limited Use — Reason for Use code 215, 216, 217, 218, 454, 696 requiredMarketed · checked 2026-09-02

Write on scriptLU code 215, 216, 217, 218, 454, 696 (patient must meet the criteria below)

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ontario Limited Use criteria — code 215, 216, 217, 218, 454, 696

Reason for Use code 215 For the treatment of emesis in cancer patients receiving highly emetogenic chemotherapy. Coverage limit: LU Authorization Period: 1 year Reason for Use code 216 For patients receiving intravenous chemotherapy or radiation therapy who have not experienced adequate control with other available anti-emetics. Coverage limit: LU Authorization Period: 1 year Reason for Use code 217 For patients receiving intravenous chemotherapy or radiation therapy who experience intolerable side effects with other anti-emetics. Coverage limit: LU Authorization Period: 1 year Reason for Use code 218 For the treatment of emesis in patients receiving radiation therapy which consists of single fraction treatment to the abdominal cavity, hemi-body irradiation and total body irradiation. Coverage limit: The therapeutic value of Ondansetron Hydrochloride more than 24 hours after the last dose of chemotherapy is unproven. Coverage limit: LU Authorization Period: 1 year Reason for Use code 454 For the treatment of emesis in cancer patients receiving moderately emetogenic chemotherapy (MEC) regimens. Coverage limit: LU Authorization Period: 1 year Reason for Use code 696 For the treatment of emesis in patients receiving palliative care who are refractory to, intolerant to, or have a contraindication to at least two other anti-emetics. Note: Pharmacists and prescribers should be informed of and stay current with a drug product's official indications in accordance with Health Canada's approved product monograph. Some aspects of the above criteria may differ from the official indications as described in the product monograph for the ondansetron product. The Executive Officer's funding of drug products is informed by advice from experts that consider evidence regarding the safety, clinical efficacy, and cost-effectiveness of drug products. Coverage limit: LU Authorization Period: 1 year

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Ondissolve ODF (Film) · DIN 02389983 Manufacturer: Takeda Canada Inc.; listing date 2013-09-27 Health Canada: Marketed since 2013-02-08 · brand ONDISSOLVE ODF · ATC A04AA01 ONDANSETRON · form Film (soluble) · route Oral · ingredients ONDANSETRON 4 MG · company Takeda canada inc · schedule Prescription

Check this DIN again · Health Canada product record

Ministry pays: $2.5450 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87545 · Verify on the e-Formulary ↗ (DIN 02389983)

Source record

DIN 02389983: Ondissolve ODF (Film) Raw flags: sec12=Y, sec3=Y Item: 562200029; group id 671; item number 1662; lccId 00102; manufacturer id TAK Source form: None; strength: 4mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $3.2720; ministry $2.5450 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02389983 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87545

Interchangeable products

Accel-Ondansetron ODT (Tablet) · DIN 02535319 · $2.5450 Auro-Ondansetron ODT (Tablet) · DIN 02511282 · $2.5450 Jamp Ondansetron ODF (Film) · DIN 02541351 · $2.5450 Mar-Ondansetron ODT Tablet · DIN 02514966 · $2.5450 Mint-Ondansetron ODT (Tablet) · DIN 02487330 · $2.5450 Ondansetron ODT (Tablet) · DIN 02481723 · $2.5450 Ondansetron ODT (Tablet) · DIN 02519232 · $2.5450 Ondansetron ODT (Tablet) · DIN 02524279 · $2.5450 PMS-Ondansetron ODT Tablet · DIN 02519445 · $2.5450 Zofran ODT (Tablet) · DIN 02239372 · not recorded

Shortage status: resolved shortage (ended 2025-11-14); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02389983

Shortage record checked 2026-09-13T08:10:21.292534+00:00

PMS-Ondansetron ODT Tablet · DIN 02519445 · 4mg ·

Limited Use — Reason for Use code 215, 216, 217, 218, 454, 696 requiredMarketed · checked 2026-09-02

Write on scriptLU code 215, 216, 217, 218, 454, 696 (patient must meet the criteria below)

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ontario Limited Use criteria — code 215, 216, 217, 218, 454, 696

Reason for Use code 215 For the treatment of emesis in cancer patients receiving highly emetogenic chemotherapy. Coverage limit: LU Authorization Period: 1 year Reason for Use code 216 For patients receiving intravenous chemotherapy or radiation therapy who have not experienced adequate control with other available anti-emetics. Coverage limit: LU Authorization Period: 1 year Reason for Use code 217 For patients receiving intravenous chemotherapy or radiation therapy who experience intolerable side effects with other anti-emetics. Coverage limit: LU Authorization Period: 1 year Reason for Use code 218 For the treatment of emesis in patients receiving radiation therapy which consists of single fraction treatment to the abdominal cavity, hemi-body irradiation and total body irradiation. Coverage limit: The therapeutic value of Ondansetron Hydrochloride more than 24 hours after the last dose of chemotherapy is unproven. Coverage limit: LU Authorization Period: 1 year Reason for Use code 454 For the treatment of emesis in cancer patients receiving moderately emetogenic chemotherapy (MEC) regimens. Coverage limit: LU Authorization Period: 1 year Reason for Use code 696 For the treatment of emesis in patients receiving palliative care who are refractory to, intolerant to, or have a contraindication to at least two other anti-emetics. Note: Pharmacists and prescribers should be informed of and stay current with a drug product's official indications in accordance with Health Canada's approved product monograph. Some aspects of the above criteria may differ from the official indications as described in the product monograph for the ondansetron product. The Executive Officer's funding of drug products is informed by advice from experts that consider evidence regarding the safety, clinical efficacy, and cost-effectiveness of drug products. Coverage limit: LU Authorization Period: 1 year

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

PMS-Ondansetron ODT Tablet · DIN 02519445 Manufacturer: Pharmascience Inc.; listing date 2022-05-31 Health Canada: Marketed since 2022-04-14 · brand PMS-ONDANSETRON ODT · ATC A04AA01 ONDANSETRON · form Tablet (orally-disintegrating) · route Oral · ingredients ONDANSETRON 4 MG · company Pharmascience inc · schedule Prescription

Check this DIN again · Health Canada product record

Ministry pays: $2.5450 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100871 · Verify on the e-Formulary ↗ (DIN 02519445)

Source record

DIN 02519445: PMS-Ondansetron ODT Tablet Raw flags: sec12=Y, sec3=Y Item: 562200029; group id 671; item number 1662; lccId 00102; manufacturer id PMS Source form: None; strength: 4mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $3.2720; ministry $2.5450 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02519445 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100871

Interchangeable products

Accel-Ondansetron ODT (Tablet) · DIN 02535319 · $2.5450 Auro-Ondansetron ODT (Tablet) · DIN 02511282 · $2.5450 Jamp Ondansetron ODF (Film) · DIN 02541351 · $2.5450 Mar-Ondansetron ODT Tablet · DIN 02514966 · $2.5450 Mint-Ondansetron ODT (Tablet) · DIN 02487330 · $2.5450 Ondansetron ODT (Tablet) · DIN 02481723 · $2.5450 Ondansetron ODT (Tablet) · DIN 02519232 · $2.5450 Ondansetron ODT (Tablet) · DIN 02524279 · $2.5450 Ondissolve ODF (Film) · DIN 02389983 · $2.5450 Zofran ODT (Tablet) · DIN 02239372 · not recorded

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02519445

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Ondansetron · DIN 02291967 · 4mg/5mL · oral liquid

Limited Use — Reason for Use code 215, 216, 217, 218, 454, 696 requiredMarketed · checked 2026-09-02

Write on scriptLU code 215, 216, 217, 218, 454, 696 (patient must meet the criteria below)

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ontario Limited Use criteria — code 215, 216, 217, 218, 454, 696

Reason for Use code 215 For the treatment of emesis in cancer patients receiving highly emetogenic chemotherapy. Coverage limit: LU Authorization Period: 1 year Reason for Use code 216 For patients receiving intravenous chemotherapy or radiation therapy who have not experienced adequate control with other available anti-emetics. Coverage limit: LU Authorization Period: 1 year Reason for Use code 217 For patients receiving intravenous chemotherapy or radiation therapy who experience intolerable side effects with other anti-emetics. Coverage limit: LU Authorization Period: 1 year Reason for Use code 218 For the treatment of emesis in patients receiving radiation therapy which consists of single fraction treatment to the abdominal cavity, hemi-body irradiation and total body irradiation. Coverage limit: The therapeutic value of Ondansetron Hydrochloride more than 24 hours after the last dose of chemotherapy is unproven. Coverage limit: LU Authorization Period: 1 year Reason for Use code 454 For the treatment of emesis in cancer patients receiving moderately emetogenic chemotherapy (MEC) regimens. Coverage limit: LU Authorization Period: 1 year Reason for Use code 696 For the treatment of emesis in patients receiving palliative care who are refractory to, intolerant to, or have a contraindication to at least two other anti-emetics. Note: Pharmacists and prescribers should be informed of and stay current with a drug product's official indications in accordance with Health Canada's approved product monograph. Some aspects of the above criteria may differ from the official indications as described in the product monograph for the ondansetron product. The Executive Officer's funding of drug products is informed by advice from experts that consider evidence regarding the safety, clinical efficacy, and cost-effectiveness of drug products. Coverage limit: LU Authorization Period: 1 year

1 brand, same coverage

Apo-Ondansetron · DIN 02291967 Manufacturer: Apotex Inc.; listing date 2009-05-20 Health Canada: Marketed since 2020-12-17 · brand APO-ONDANSETRON · ATC A04AA01 ONDANSETRON · form Solution · route Oral · ingredients ONDANSETRON (ONDANSETRON HYDROCHLORIDE DIHYDRATE) 4 MG/5ML · company Apotex inc · schedule Prescription

Check this DIN again · Health Canada product record

Apo-Ondansetron: Formulary list price $0.7952/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.7952 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77733 · Verify on the e-Formulary ↗ (DIN 02291967)

Source record

DIN 02291967: Apo-Ondansetron Raw flags: sec12=Y, sec3=Y Item: 562200025; group id 671; item number 1664; lccId 00102; manufacturer id APX Source form: O/L; strength: 4mg/5mL Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $0.7952; ministry $0.7952 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02291967 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77733

Interchangeable products

Jamp Ondansetron · DIN 02490617 · $0.7952 Mint-Ondansetron Solution · DIN 02524090 · $0.7952 Zofran · DIN 02229639 · not recorded

Shortage status: active shortage (reported 2025-12-30, last updated 2026-01-02); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02291967

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp Ondansetron · DIN 02490617 · 4mg/5mL · oral liquid

Limited Use — Reason for Use code 215, 216, 217, 218, 454, 696 requiredMarketed · checked 2026-09-02

Write on scriptLU code 215, 216, 217, 218, 454, 696 (patient must meet the criteria below)

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ontario Limited Use criteria — code 215, 216, 217, 218, 454, 696

Reason for Use code 215 For the treatment of emesis in cancer patients receiving highly emetogenic chemotherapy. Coverage limit: LU Authorization Period: 1 year Reason for Use code 216 For patients receiving intravenous chemotherapy or radiation therapy who have not experienced adequate control with other available anti-emetics. Coverage limit: LU Authorization Period: 1 year Reason for Use code 217 For patients receiving intravenous chemotherapy or radiation therapy who experience intolerable side effects with other anti-emetics. Coverage limit: LU Authorization Period: 1 year Reason for Use code 218 For the treatment of emesis in patients receiving radiation therapy which consists of single fraction treatment to the abdominal cavity, hemi-body irradiation and total body irradiation. Coverage limit: The therapeutic value of Ondansetron Hydrochloride more than 24 hours after the last dose of chemotherapy is unproven. Coverage limit: LU Authorization Period: 1 year Reason for Use code 454 For the treatment of emesis in cancer patients receiving moderately emetogenic chemotherapy (MEC) regimens. Coverage limit: LU Authorization Period: 1 year Reason for Use code 696 For the treatment of emesis in patients receiving palliative care who are refractory to, intolerant to, or have a contraindication to at least two other anti-emetics. Note: Pharmacists and prescribers should be informed of and stay current with a drug product's official indications in accordance with Health Canada's approved product monograph. Some aspects of the above criteria may differ from the official indications as described in the product monograph for the ondansetron product. The Executive Officer's funding of drug products is informed by advice from experts that consider evidence regarding the safety, clinical efficacy, and cost-effectiveness of drug products. Coverage limit: LU Authorization Period: 1 year

1 brand, same coverage

Jamp Ondansetron · DIN 02490617 Manufacturer: Jamp Pharma Corporation; listing date 2020-06-30 Health Canada: Marketed since 2020-04-22 · brand JAMP ONDANSETRON · ATC A04AA01 ONDANSETRON · form Solution · route Oral · ingredients ONDANSETRON (ONDANSETRON HYDROCHLORIDE DIHYDRATE) 4 MG/5ML · company Jamp pharma corporation · schedule Prescription

Check this DIN again · Health Canada product record

Jamp Ondansetron: Formulary list price $0.7952/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.7952 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98068 · Verify on the e-Formulary ↗ (DIN 02490617)

Source record

DIN 02490617: Jamp Ondansetron Raw flags: sec12=Y, sec3=Y Item: 562200025; group id 671; item number 1664; lccId 00102; manufacturer id JPC Source form: O/L; strength: 4mg/5mL Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $0.7952; ministry $0.7952 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02490617 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98068

Interchangeable products

Apo-Ondansetron · DIN 02291967 · $0.7952 Mint-Ondansetron Solution · DIN 02524090 · $0.7952 Zofran · DIN 02229639 · not recorded

Shortage status: active shortage (reported not recorded, estimated to end 2026-12-11, last updated 2026-08-26); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02490617

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mint-Ondansetron Solution · DIN 02524090 · 4mg/5mL · oral liquid

Limited Use — Reason for Use code 215, 216, 217, 218, 454, 696 requiredMarketed · checked 2026-09-02

Write on scriptLU code 215, 216, 217, 218, 454, 696 (patient must meet the criteria below)

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ontario Limited Use criteria — code 215, 216, 217, 218, 454, 696

Reason for Use code 215 For the treatment of emesis in cancer patients receiving highly emetogenic chemotherapy. Coverage limit: LU Authorization Period: 1 year Reason for Use code 216 For patients receiving intravenous chemotherapy or radiation therapy who have not experienced adequate control with other available anti-emetics. Coverage limit: LU Authorization Period: 1 year Reason for Use code 217 For patients receiving intravenous chemotherapy or radiation therapy who experience intolerable side effects with other anti-emetics. Coverage limit: LU Authorization Period: 1 year Reason for Use code 218 For the treatment of emesis in patients receiving radiation therapy which consists of single fraction treatment to the abdominal cavity, hemi-body irradiation and total body irradiation. Coverage limit: The therapeutic value of Ondansetron Hydrochloride more than 24 hours after the last dose of chemotherapy is unproven. Coverage limit: LU Authorization Period: 1 year Reason for Use code 454 For the treatment of emesis in cancer patients receiving moderately emetogenic chemotherapy (MEC) regimens. Coverage limit: LU Authorization Period: 1 year Reason for Use code 696 For the treatment of emesis in patients receiving palliative care who are refractory to, intolerant to, or have a contraindication to at least two other anti-emetics. Note: Pharmacists and prescribers should be informed of and stay current with a drug product's official indications in accordance with Health Canada's approved product monograph. Some aspects of the above criteria may differ from the official indications as described in the product monograph for the ondansetron product. The Executive Officer's funding of drug products is informed by advice from experts that consider evidence regarding the safety, clinical efficacy, and cost-effectiveness of drug products. Coverage limit: LU Authorization Period: 1 year

1 brand, same coverage

Mint-Ondansetron Solution · DIN 02524090 Manufacturer: Mint Pharmaceuticals Inc.; listing date 2024-12-30 Health Canada: Marketed since 2024-09-11 · brand MINT-ONDANSETRON SOLUTION · ATC A04AA01 ONDANSETRON · form Solution · route Oral · ingredients ONDANSETRON (ONDANSETRON HYDROCHLORIDE) 4 MG/5ML · company Mint pharmaceuticals inc · schedule Prescription

Check this DIN again · Health Canada product record

Mint-Ondansetron Solution: Formulary list price $0.7952/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.7952 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101313 · Verify on the e-Formulary ↗ (DIN 02524090)

Source record

DIN 02524090: Mint-Ondansetron Solution Raw flags: sec12=Y, sec3=Y Item: 562200025; group id 671; item number 1664; lccId 00102; manufacturer id MIN Source form: O/L; strength: 4mg/5mL Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $0.7952; ministry $0.7952 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02524090 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101313

Interchangeable products

Apo-Ondansetron · DIN 02291967 · $0.7952 Jamp Ondansetron · DIN 02490617 · $0.7952 Zofran · DIN 02229639 · not recorded

Shortage status: resolved shortage (ended 2026-09-02); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02524090

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Accel-Ondansetron · DIN 02478927 · 4mg · tablet

Limited Use — Reason for Use code 215, 216, 217, 218, 454, 696 requiredMarketed · checked 2026-09-02

Write on scriptLU code 215, 216, 217, 218, 454, 696 (patient must meet the criteria below)

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ontario Limited Use criteria — code 215, 216, 217, 218, 454, 696

Reason for Use code 215 For the treatment of emesis in cancer patients receiving highly emetogenic chemotherapy. Coverage limit: LU Authorization Period: 1 year Reason for Use code 216 For patients receiving intravenous chemotherapy or radiation therapy who have not experienced adequate control with other available anti-emetics. Coverage limit: LU Authorization Period: 1 year Reason for Use code 217 For patients receiving intravenous chemotherapy or radiation therapy who experience intolerable side effects with other anti-emetics. Coverage limit: LU Authorization Period: 1 year Reason for Use code 218 For the treatment of emesis in patients receiving radiation therapy which consists of single fraction treatment to the abdominal cavity, hemi-body irradiation and total body irradiation. Coverage limit: The therapeutic value of Ondansetron Hydrochloride more than 24 hours after the last dose of chemotherapy is unproven. Coverage limit: LU Authorization Period: 1 year Reason for Use code 454 For the treatment of emesis in cancer patients receiving moderately emetogenic chemotherapy (MEC) regimens. Coverage limit: LU Authorization Period: 1 year Reason for Use code 696 For the treatment of emesis in patients receiving palliative care who are refractory to, intolerant to, or have a contraindication to at least two other anti-emetics. Note: Pharmacists and prescribers should be informed of and stay current with a drug product's official indications in accordance with Health Canada's approved product monograph. Some aspects of the above criteria may differ from the official indications as described in the product monograph for the ondansetron product. The Executive Officer's funding of drug products is informed by advice from experts that consider evidence regarding the safety, clinical efficacy, and cost-effectiveness of drug products. Coverage limit: LU Authorization Period: 1 year

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Accel-Ondansetron · DIN 02478927 Manufacturer: Accel Pharma Inc.; listing date 2019-12-20 Health Canada: Marketed since 2019-09-19 · brand ACCEL-ONDANSETRON · ATC A04AA01 ONDANSETRON · form Tablet · route Oral · ingredients ONDANSETRON (ONDANSETRON HYDROCHLORIDE DIHYDRATE) 4 MG · company Accel pharma inc · schedule Prescription

Check this DIN again · Health Canada product record

Accel-Ondansetron: Formulary list price $2.5450/unit (unit not stated in source; not the patient's cost)

Ministry pays: $2.5450 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96963 · Verify on the e-Formulary ↗ (DIN 02478927)

Source record

DIN 02478927: Accel-Ondansetron Raw flags: sec12=Y, sec3=Y Item: 562200022; group id 671; item number 1665; lccId 00102; manufacturer id ACC Source form: Tab; strength: 4mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $2.5450; ministry $2.5450 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02478927 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96963

Interchangeable products

Apo-Ondansetron · DIN 02288184 · $2.5450 Jamp-Ondansetron · DIN 02313685 · $2.5450 Mar-Ondansetron · DIN 02371731 · $2.5450 Mint-Ondansetron · DIN 02305259 · $2.5450 Mylan-Ondansetron · DIN 02297868 · $2.5450 Nat-Ondansetron · DIN 02417839 · $2.5450 Ondansetron · DIN 02421402 · $2.5450 Ondansetron · DIN 02541424 · $2.5450 PMS-Ondansetron · DIN 02258188 · $2.5450 Sandoz Ondansetron · DIN 02274310 · $2.5450 Septa-Ondansetron · DIN 02376091 · $2.5450 Teva-Ondansetron · DIN 02296349 · $2.5450 Zofran · DIN 02213567 · not recorded

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02478927

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Ondansetron · DIN 02288184 · 4mg · tablet

Limited Use — Reason for Use code 215, 216, 217, 218, 454, 696 requiredMarketed · checked 2026-09-02

Write on scriptLU code 215, 216, 217, 218, 454, 696 (patient must meet the criteria below)

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ontario Limited Use criteria — code 215, 216, 217, 218, 454, 696

Reason for Use code 215 For the treatment of emesis in cancer patients receiving highly emetogenic chemotherapy. Coverage limit: LU Authorization Period: 1 year Reason for Use code 216 For patients receiving intravenous chemotherapy or radiation therapy who have not experienced adequate control with other available anti-emetics. Coverage limit: LU Authorization Period: 1 year Reason for Use code 217 For patients receiving intravenous chemotherapy or radiation therapy who experience intolerable side effects with other anti-emetics. Coverage limit: LU Authorization Period: 1 year Reason for Use code 218 For the treatment of emesis in patients receiving radiation therapy which consists of single fraction treatment to the abdominal cavity, hemi-body irradiation and total body irradiation. Coverage limit: The therapeutic value of Ondansetron Hydrochloride more than 24 hours after the last dose of chemotherapy is unproven. Coverage limit: LU Authorization Period: 1 year Reason for Use code 454 For the treatment of emesis in cancer patients receiving moderately emetogenic chemotherapy (MEC) regimens. Coverage limit: LU Authorization Period: 1 year Reason for Use code 696 For the treatment of emesis in patients receiving palliative care who are refractory to, intolerant to, or have a contraindication to at least two other anti-emetics. Note: Pharmacists and prescribers should be informed of and stay current with a drug product's official indications in accordance with Health Canada's approved product monograph. Some aspects of the above criteria may differ from the official indications as described in the product monograph for the ondansetron product. The Executive Officer's funding of drug products is informed by advice from experts that consider evidence regarding the safety, clinical efficacy, and cost-effectiveness of drug products. Coverage limit: LU Authorization Period: 1 year

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Apo-Ondansetron · DIN 02288184 Manufacturer: Apotex Inc.; listing date 2007-03-09 Health Canada: Marketed since 2006-11-16 · brand APO-ONDANSETRON · ATC A04AA01 ONDANSETRON · form Tablet · route Oral · ingredients ONDANSETRON (ONDANSETRON HYDROCHLORIDE DIHYDRATE) 4 MG · company Apotex inc · schedule Prescription

Check this DIN again · Health Canada product record

Ministry pays: $2.5450 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77362 · Verify on the e-Formulary ↗ (DIN 02288184)

Source record

DIN 02288184: Apo-Ondansetron Raw flags: sec12=Y, sec3=Y Item: 562200022; group id 671; item number 1665; lccId 00102; manufacturer id APX Source form: Tab; strength: 4mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $3.3495; ministry $2.5450 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02288184 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77362

Interchangeable products

Accel-Ondansetron · DIN 02478927 · $2.5450 Jamp-Ondansetron · DIN 02313685 · $2.5450 Mar-Ondansetron · DIN 02371731 · $2.5450 Mint-Ondansetron · DIN 02305259 · $2.5450 Mylan-Ondansetron · DIN 02297868 · $2.5450 Nat-Ondansetron · DIN 02417839 · $2.5450 Ondansetron · DIN 02421402 · $2.5450 Ondansetron · DIN 02541424 · $2.5450 PMS-Ondansetron · DIN 02258188 · $2.5450 Sandoz Ondansetron · DIN 02274310 · $2.5450 Septa-Ondansetron · DIN 02376091 · $2.5450 Teva-Ondansetron · DIN 02296349 · $2.5450 Zofran · DIN 02213567 · not recorded

Shortage status: shortage reported ended 2026-04-02 (report last updated 2026-04-02); confirm supply with the pharmacy; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02288184

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp-Ondansetron · DIN 02313685 · 4mg · tablet

Limited Use — Reason for Use code 215, 216, 217, 218, 454, 696 requiredMarketed · checked 2026-09-02

Write on scriptLU code 215, 216, 217, 218, 454, 696 (patient must meet the criteria below)

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ontario Limited Use criteria — code 215, 216, 217, 218, 454, 696

Reason for Use code 215 For the treatment of emesis in cancer patients receiving highly emetogenic chemotherapy. Coverage limit: LU Authorization Period: 1 year Reason for Use code 216 For patients receiving intravenous chemotherapy or radiation therapy who have not experienced adequate control with other available anti-emetics. Coverage limit: LU Authorization Period: 1 year Reason for Use code 217 For patients receiving intravenous chemotherapy or radiation therapy who experience intolerable side effects with other anti-emetics. Coverage limit: LU Authorization Period: 1 year Reason for Use code 218 For the treatment of emesis in patients receiving radiation therapy which consists of single fraction treatment to the abdominal cavity, hemi-body irradiation and total body irradiation. Coverage limit: The therapeutic value of Ondansetron Hydrochloride more than 24 hours after the last dose of chemotherapy is unproven. Coverage limit: LU Authorization Period: 1 year Reason for Use code 454 For the treatment of emesis in cancer patients receiving moderately emetogenic chemotherapy (MEC) regimens. Coverage limit: LU Authorization Period: 1 year Reason for Use code 696 For the treatment of emesis in patients receiving palliative care who are refractory to, intolerant to, or have a contraindication to at least two other anti-emetics. Note: Pharmacists and prescribers should be informed of and stay current with a drug product's official indications in accordance with Health Canada's approved product monograph. Some aspects of the above criteria may differ from the official indications as described in the product monograph for the ondansetron product. The Executive Officer's funding of drug products is informed by advice from experts that consider evidence regarding the safety, clinical efficacy, and cost-effectiveness of drug products. Coverage limit: LU Authorization Period: 1 year

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Jamp-Ondansetron · DIN 02313685 Manufacturer: Jamp Pharma Corporation; listing date 2009-01-30 Health Canada: Marketed since 2008-09-26 · brand JAMP-ONDANSETRON · ATC A04AA01 ONDANSETRON · form Tablet · route Oral · ingredients ONDANSETRON (ONDANSETRON HYDROCHLORIDE) 4 MG · company Jamp pharma corporation · schedule Prescription

Check this DIN again · Health Canada product record

Ministry pays: $2.5450 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79919 · Verify on the e-Formulary ↗ (DIN 02313685)

Source record

DIN 02313685: Jamp-Ondansetron Raw flags: sec12=Y, sec3=Y Item: 562200022; group id 671; item number 1665; lccId 00102; manufacturer id JPC Source form: Tab; strength: 4mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $3.3495; ministry $2.5450 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02313685 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79919

Interchangeable products

Accel-Ondansetron · DIN 02478927 · $2.5450 Apo-Ondansetron · DIN 02288184 · $2.5450 Mar-Ondansetron · DIN 02371731 · $2.5450 Mint-Ondansetron · DIN 02305259 · $2.5450 Mylan-Ondansetron · DIN 02297868 · $2.5450 Nat-Ondansetron · DIN 02417839 · $2.5450 Ondansetron · DIN 02421402 · $2.5450 Ondansetron · DIN 02541424 · $2.5450 PMS-Ondansetron · DIN 02258188 · $2.5450 Sandoz Ondansetron · DIN 02274310 · $2.5450 Septa-Ondansetron · DIN 02376091 · $2.5450 Teva-Ondansetron · DIN 02296349 · $2.5450 Zofran · DIN 02213567 · not recorded

Shortage status: resolved shortage (ended 2018-04-27); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02313685

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mar-Ondansetron · DIN 02371731 · 4mg · tablet

Limited Use — Reason for Use code 215, 216, 217, 218, 454, 696 requiredMarketed · checked 2026-09-02

Write on scriptLU code 215, 216, 217, 218, 454, 696 (patient must meet the criteria below)

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ontario Limited Use criteria — code 215, 216, 217, 218, 454, 696

Reason for Use code 215 For the treatment of emesis in cancer patients receiving highly emetogenic chemotherapy. Coverage limit: LU Authorization Period: 1 year Reason for Use code 216 For patients receiving intravenous chemotherapy or radiation therapy who have not experienced adequate control with other available anti-emetics. Coverage limit: LU Authorization Period: 1 year Reason for Use code 217 For patients receiving intravenous chemotherapy or radiation therapy who experience intolerable side effects with other anti-emetics. Coverage limit: LU Authorization Period: 1 year Reason for Use code 218 For the treatment of emesis in patients receiving radiation therapy which consists of single fraction treatment to the abdominal cavity, hemi-body irradiation and total body irradiation. Coverage limit: The therapeutic value of Ondansetron Hydrochloride more than 24 hours after the last dose of chemotherapy is unproven. Coverage limit: LU Authorization Period: 1 year Reason for Use code 454 For the treatment of emesis in cancer patients receiving moderately emetogenic chemotherapy (MEC) regimens. Coverage limit: LU Authorization Period: 1 year Reason for Use code 696 For the treatment of emesis in patients receiving palliative care who are refractory to, intolerant to, or have a contraindication to at least two other anti-emetics. Note: Pharmacists and prescribers should be informed of and stay current with a drug product's official indications in accordance with Health Canada's approved product monograph. Some aspects of the above criteria may differ from the official indications as described in the product monograph for the ondansetron product. The Executive Officer's funding of drug products is informed by advice from experts that consider evidence regarding the safety, clinical efficacy, and cost-effectiveness of drug products. Coverage limit: LU Authorization Period: 1 year

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Mar-Ondansetron · DIN 02371731 Manufacturer: Marcan Pharmaceuticals Inc.; listing date 2012-01-19 Health Canada: Marketed since 2012-12-21 · brand MAR-ONDANSETRON · ATC A04AA01 ONDANSETRON · form Tablet · route Oral · ingredients ONDANSETRON (ONDANSETRON HYDROCHLORIDE) 4 MG · company Marcan pharmaceuticals inc · schedule Prescription

Check this DIN again · Health Canada product record

Ministry pays: $2.5450 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85687 · Verify on the e-Formulary ↗ (DIN 02371731)

Source record

DIN 02371731: Mar-Ondansetron Raw flags: sec12=Y, sec3=Y Item: 562200022; group id 671; item number 1665; lccId 00102; manufacturer id MAR Source form: Tab; strength: 4mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $3.3495; ministry $2.5450 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02371731 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=85687

Interchangeable products

Accel-Ondansetron · DIN 02478927 · $2.5450 Apo-Ondansetron · DIN 02288184 · $2.5450 Jamp-Ondansetron · DIN 02313685 · $2.5450 Mint-Ondansetron · DIN 02305259 · $2.5450 Mylan-Ondansetron · DIN 02297868 · $2.5450 Nat-Ondansetron · DIN 02417839 · $2.5450 Ondansetron · DIN 02421402 · $2.5450 Ondansetron · DIN 02541424 · $2.5450 PMS-Ondansetron · DIN 02258188 · $2.5450 Sandoz Ondansetron · DIN 02274310 · $2.5450 Septa-Ondansetron · DIN 02376091 · $2.5450 Teva-Ondansetron · DIN 02296349 · $2.5450 Zofran · DIN 02213567 · not recorded

Shortage status: resolved shortage (ended 2019-07-10); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02371731

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mint-Ondansetron · DIN 02305259 · 4mg · tablet

Limited Use — Reason for Use code 215, 216, 217, 218, 454, 696 requiredMarketed · checked 2026-09-02

Write on scriptLU code 215, 216, 217, 218, 454, 696 (patient must meet the criteria below)

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ontario Limited Use criteria — code 215, 216, 217, 218, 454, 696

Reason for Use code 215 For the treatment of emesis in cancer patients receiving highly emetogenic chemotherapy. Coverage limit: LU Authorization Period: 1 year Reason for Use code 216 For patients receiving intravenous chemotherapy or radiation therapy who have not experienced adequate control with other available anti-emetics. Coverage limit: LU Authorization Period: 1 year Reason for Use code 217 For patients receiving intravenous chemotherapy or radiation therapy who experience intolerable side effects with other anti-emetics. Coverage limit: LU Authorization Period: 1 year Reason for Use code 218 For the treatment of emesis in patients receiving radiation therapy which consists of single fraction treatment to the abdominal cavity, hemi-body irradiation and total body irradiation. Coverage limit: The therapeutic value of Ondansetron Hydrochloride more than 24 hours after the last dose of chemotherapy is unproven. Coverage limit: LU Authorization Period: 1 year Reason for Use code 454 For the treatment of emesis in cancer patients receiving moderately emetogenic chemotherapy (MEC) regimens. Coverage limit: LU Authorization Period: 1 year Reason for Use code 696 For the treatment of emesis in patients receiving palliative care who are refractory to, intolerant to, or have a contraindication to at least two other anti-emetics. Note: Pharmacists and prescribers should be informed of and stay current with a drug product's official indications in accordance with Health Canada's approved product monograph. Some aspects of the above criteria may differ from the official indications as described in the product monograph for the ondansetron product. The Executive Officer's funding of drug products is informed by advice from experts that consider evidence regarding the safety, clinical efficacy, and cost-effectiveness of drug products. Coverage limit: LU Authorization Period: 1 year

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Mint-Ondansetron · DIN 02305259 Manufacturer: Mint Pharmaceuticals Inc.; listing date 2008-12-23 Health Canada: Marketed since 2013-10-31 · brand MINT-ONDANSETRON · ATC A04AA01 ONDANSETRON · form Tablet · route Oral · ingredients ONDANSETRON (ONDANSETRON HYDROCHLORIDE) 4 MG · company Mint pharmaceuticals inc · schedule Prescription

Check this DIN again · Health Canada product record

Ministry pays: $2.5450 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79079 · Verify on the e-Formulary ↗ (DIN 02305259)

Source record

DIN 02305259: Mint-Ondansetron Raw flags: sec12=Y, sec3=Y Item: 562200022; group id 671; item number 1665; lccId 00102; manufacturer id MIN Source form: Tab; strength: 4mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $3.3495; ministry $2.5450 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02305259 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79079

Interchangeable products

Accel-Ondansetron · DIN 02478927 · $2.5450 Apo-Ondansetron · DIN 02288184 · $2.5450 Jamp-Ondansetron · DIN 02313685 · $2.5450 Mar-Ondansetron · DIN 02371731 · $2.5450 Mylan-Ondansetron · DIN 02297868 · $2.5450 Nat-Ondansetron · DIN 02417839 · $2.5450 Ondansetron · DIN 02421402 · $2.5450 Ondansetron · DIN 02541424 · $2.5450 PMS-Ondansetron · DIN 02258188 · $2.5450 Sandoz Ondansetron · DIN 02274310 · $2.5450 Septa-Ondansetron · DIN 02376091 · $2.5450 Teva-Ondansetron · DIN 02296349 · $2.5450 Zofran · DIN 02213567 · not recorded

Shortage status: resolved shortage (ended 2018-03-09); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02305259

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Look up one drug

ONDANSETRON HCL DIHYDRATE

Auro-Ondansetron Injection · DIN 02491524 · 2mg/mL · injection solution-2mL Pk

Ondansetron Injection USP · DIN 02464578 · 2mg/mL · injection solution-2mL Pk

Auro-Ondansetron Injection · DIN 02491532 · 2mg/mL · injection solution-4mL Pk

Ondansetron Injection USP · PIN 09857602 · 2mg/mL · injection solution-4mL Pk

Zofran · PIN 09857324 · 2mg/mL · injection solution-4mL Pk

Zofran · DIN 02213745 · 2mg/mL · injection solution-2mL Pk

ONDANSETRON HYDROCHLORIDE

Accel-Ondansetron ODT (Tablet) · DIN 02535319 · 4mg ·

Auro-Ondansetron ODT (Tablet) · DIN 02511282 · 4mg ·

Jamp Ondansetron ODF (Film) · DIN 02541351 · 4mg ·

Mar-Ondansetron ODT Tablet · DIN 02514966 · 4mg ·

Mint-Ondansetron ODT (Tablet) · DIN 02487330 · 4mg ·

Ondansetron ODT (Tablet) · DIN 02481723 · 4mg ·

Ondansetron ODT (Tablet) · DIN 02519232 · 4mg ·

Ondansetron ODT (Tablet) · DIN 02524279 · 4mg ·

Ondissolve ODF (Film) · DIN 02389983 · 4mg ·

PMS-Ondansetron ODT Tablet · DIN 02519445 · 4mg ·

Apo-Ondansetron · DIN 02291967 · 4mg/5mL · oral liquid

Jamp Ondansetron · DIN 02490617 · 4mg/5mL · oral liquid

Mint-Ondansetron Solution · DIN 02524090 · 4mg/5mL · oral liquid

Accel-Ondansetron · DIN 02478927 · 4mg · tablet

Apo-Ondansetron · DIN 02288184 · 4mg · tablet

Jamp-Ondansetron · DIN 02313685 · 4mg · tablet

Mar-Ondansetron · DIN 02371731 · 4mg · tablet

Mint-Ondansetron · DIN 02305259 · 4mg · tablet

Matched class: 56:22 Antiemetics and Antinauseants

GRANISETRON HCL

NETUPITANT & PALONOSETRON HYDROCHLORIDE

NABILONE

APREPITANT

DOXYLAMINE SUCCINATE AND PYRIDOXINE HCL

MECLIZINE HCL

DIMENHYDRINATE

Availability

Other review policies